| 24.54 -0.7 (-2.77%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 29.8 | 1-year : | 34.81 |
| Resists | First : | 25.52 | Second : | 29.8 |
| Pivot price | 22.77 |
|||
| Supports | First : | 22.2 |
Second : | 20.15 |
| MAs | MA(5) : | 24.36 |
MA(20) : | 22.63 |
| MA(100) : | 24.41 |
MA(250) : | 23.85 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 87.5 |
D(3) : | 92.3 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 35.86 | Low : | 15.59 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ STAA ] has closed below upper band by 13.8%. Bollinger Bands are 19.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.26 - 25.39 | 25.39 - 25.47 |
| Low: | 24.02 - 24.19 | 24.19 - 24.29 |
| Close: | 24.32 - 24.57 | 24.57 - 24.73 |
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Fri, 30 Oct 2026
STAAR Surgical Company (STAA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 29 Oct 2026
STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific - citybiz
Thu, 29 Oct 2026
A former STAAR executive will return to lead its Asia-Pacific business outside China - Stock Titan
Thu, 29 Oct 2026
STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific - Yahoo Finance
Wed, 28 Oct 2026
STAAR Surgical Company (STAA) Stock Forecasts - Yahoo Finance
Tue, 27 Oct 2026
STAAR Surgical to Participate in Upcoming Investor Conferences - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 50 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 111.5 (%) |
| Shares Short | 3,740 (K) |
| Shares Short P.Month | 4,260 (K) |
| EPS | 0.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.28 |
| Profit Margin | 1.1 % |
| Operating Margin | 10.8 % |
| Return on Assets (ttm) | 5.6 % |
| Return on Equity (ttm) | 1 % |
| Qtrly Rev. Growth | 111 % |
| Gross Profit (p.s.) | 5.18 |
| Sales Per Share | 6.77 |
| EBITDA (p.s.) | 0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 15 (M) |
| PE Ratio | 307 |
| PEG Ratio | 0.7 |
| Price to Book value | 3.36 |
| Price to Sales | 3.62 |
| Price to Cash Flow | -378.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|